Barclays
IMUX icon

Barclays’s Immunic IMUX Stock Holding History

Barclays’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-158
Closed -$17K – 7111
2018
Q3 		$17K Buy
+158
New +$412K ﹤0.01% 6510

Other funds holding IMUX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Barclays's IMUX Position: Q1 2026 in Review

Barclays increased its Immunic (IMUX) stake by 493% in Q1 2026, buying an estimated $1.81K and bringing the position to 243 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #4825.

Barclays first reported a position in IMUX in Q2 2014 and has held it in 31 quarters since. The position peaked at $217K in Q4 2021. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • Barclays held 243 shares of Immunic worth $2.69K as of Q1 2026.
  • Barclays bought 202 Immunic shares in Q1 2026, an estimated $1.81K.
  • Immunic made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4825 holding.
  • Barclays first reported a position in Immunic in Q2 2014 and has held it in 31 quarters since.
  • Barclays's Immunic position peaked at $217K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.